EuroPCR 2022: Late-breaking Science Video Collection
Published: 13 May 2022
EuroPCR 22: Short-Term Clinical Outcomes of ACURATE neo2™
- EuroPCR 22: AQVA Study Shows Superiority in QFR-Based Virtual PCI Arm
- EuroPCR 22: Patient-Level Pooled Analysis of Ultrasound RDN in radiance-HTN SOLO & Trio
- EuroPCR 22: Optimize PRO Interim Analysis Finds New Technique is "Best-in-Class"
- EuroPCR 22: MASTER-DAPT Sub-Analysis Shows Consistent Results in Complex PCI Patients
- EuroPCR 22: CRUZ-HBR Indicates Use Of Supraflux™ Cruz Stent Is Favourable
- EuroPCR 22: ASTRO-TAVI Shows Improved Neurological Outcomes With Neurointervention
- EuroPCR 22: Short-Term Clinical Outcomes of ACURATE neo2™
- EuroPCR 22: DECISION QFR Shows Increased Practicability and Shorter Procedure Time for Revasc.
- EuroPCR 22: SYNERGY™ Non-inferior to BioMatrix NeoFlex in OCT SORT-OUT VIII
- EuroPCR 22: ROLEX Study Finds Promising Results in CAD Pts With the Resolute Onyx
- EuroPCR 22: Balloon Vs Self-Expanding Valves in Valve-in-Valve TAVI
- EuroPCR 22: MitraClip in Atrial Functional Mitral Regurgitation
- EuroPCR 22: SCB with Micro-Reservoir Technology in Coronary Lesions
- EuroPCR 22: FORWARD PRO Study Shows No Durability Issues After 3 Years
- EuroPCR 22: DEB & DES in the Treatment of Diffuse CAD
- EuroPCR 22: EASTBOURNE Registry indicates Satefy of Sirolimus-Coated Balloon
- EuroPCR 22: JenaValve TAVR System for the Treatment of Aortic Regurgitation
- EuroPCR 22: Transcatheter Tricuspid Valve Repair with PASCAL System
- EuroPCR 2022: ALIGN-EFS Finds 100% Procedural Success Rate Using JenaValve Trilogy in Pts With AS
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science trials and spotlight questions that could change treatment strategies in interventional cardiology.
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
View from the Thoraxcenter
Background of This Study
Background of the ITAL-neo registry has to be searched on the available evidence produced so far in literature demonstrating the non-negligible incidence of more than mild paravalvular leak with the use of the early generation ACURATE neo in the context of TAVI. For this reason, the producing company, the Boston scientific, has launched on the market at the end of September, 2020 the new iteration, called ACURATE neo2.
Study Design and Patient Population
The device used in the study is the ACURATE neo2. This valve maintain the key feature of the previous generation valve, but incorporates some engineering refinement such as the presence of a radio pack marker on the delivery system, able to guarantee a more precise implantation, but also the presence of a total outer pericardial skirts which reach the upper crown and with an active technology able to guarantee a more synchronous adaptation to the native annulus, with the potential to reduce the incidence of moderate or greater paravalvular leak.
Study Design and Patient Population
Our study is a retrospective, observational, multi-center, independent registry. We enrolled 900 patients consecutive, affected by severe aortic valve stenosis treated in 13 Italian centers which received both generation device. Of the 900 patients, 680 received the earlier generation device, whereas 220 were treated with the ACURATE neo2 valve. To account for the non-randomized nature of the study, we perform the 1:1 propensity score match in order to have the final results of 205 pairs of patients.
The primary endpoint is the incidence of moderate or greater paravalvular leaks at pre-discharge echocardiographic assessment. Whereas secondary endpoints are technical success, but also some short-term clinical outcome intended as 90 days safety, 90 days efficacy, and a single component of the pre-specified composite endpoint. All the endpoints were assessed according to the model BARC three criteria. We demonstrate a significant reduction of the primary endpoint with the use of new generation ACURATE neo2 that occurred in 3.5% of the patients, compare with 11.2% of patients treated with the early generation device. Also the technical success were high in both groups with comparable results. And this is intuitive since this definition does not include the presence of more moderate or greater paravalvular leaks, but also data concerning the short-term clinical outcome are encouraging because we see a higher number of safety and efficacy 90-day success with new generation device.
My take-home message is that ACURATE neo2 is improve its performance especially in the context to reduce paravalvular leak. And I think now this valve is ready to be used in a broad and large population of patients, in the context of TAVI.
Further Study Required
We need randomised controlled trial to confirm our preliminary results.